EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

Kevin L Winthrop iD, Séverine Vermeire, Millie D Long iD, Julian Panés, Siew C Ng, Nicole Kulisek, Rajiv Mundayat, Nervin Lawendy, Ivana Vranic, Irene Modesto, Chinyu Su, Gil Y Melmed

Inflammatory Bowel Diseases · 2023

DOI: 10.1093/ibd/izac063 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Kevin L Winthrop und 11 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Herpes Zoster. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report herpes zoster (HZ) incidence and risk factors in the tofacitinib UC clinical program (up to 7.8 years).

Methods

Proportions and incidence rates (IRs; unique patients with events/100 patient-years) of HZ were evaluated in 4 cohorts: Induction (phase 2 and 3 induction study data), Maintenance (phase 3 maintenance study data), Overall (data from all phase 2, 3, and open-label, long-term extension studies), and Overall plus interim 6-month phase 3b and 4 data. Herpes zoster risk factors were assessed by Cox regression analysis.

Results

In the Induction and Maintenance Cohorts, IRs for HZ (nonserious and serious) were numerically higher with tofacitinib 10 mg twice daily (BID) vs placebo and tofacitinib 10 vs 5 mg BID, respectively. With all tofacitinib doses (5 or 10 mg BID), IRs (95% confidence intervals) for HZ in the Overall and Overall plus phase 3b/4 Cohorts (total exposure, 2814.4 and 2999.7 patient-years, respectively) were 3.38 (2.73-4.15) and 3.30 (2.67-4.04), respectively. In the Overall plus phase 3b/4 Cohort, >90% of HZ were nonserious; >90% were mild/moderate; >90% resolved without discontinuing tofacitinib; 0.6% of patients had multiple HZ events. Herpes zoster IRs were stable when analyzed by 6-month intervals up to >30 months. Herpes zoster risk factors included older age, lower weight, geographic region, and prior tumor necrosis factor inhibitor (TNFi) failure.

Conclusions

Most HZ events were mild/moderate. Herpes zoster IRs remained stable over 7.8 years of exposure. Older age, lower weight, geographic region, and prior TNFi failure were associated with increased HZ risk. ClinicalTrials.gov NCT00787202;NCT01465763;NCT01458951;NCT01458574;NCT01470612;NCT03281304

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHerpes ZosterHumansPiperidinesPyrimidinesHerpesvirus 3, Human

Stichwörter der Autor:innen

herpes zostertofacitinibulcerative colitis

Substanzen

tofacitinibPiperidinesPyrimidines

Autor:innen und Institutionen

  • Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
  • University of North Carolina, Center for Gastrointestinal Biology and Disease, Chapel Hill, North Carolina, USA.
  • Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
  • Institute of Digestive Disease, Department of Medicine and Therapeutics, LKS Institute of Health Science, Chinese University of Hong Kong, Hong Kong.
  • Pfizer Inc, Collegeville, Pennsylvania, USA.

ORCID-Profile: Kevin L Winthrop, Millie D Long

Förderung

  • Pfizer

Zitieren

APA

Winthrop, K. L., Vermeire, S., Long, M. D., Panés, J., Ng, S. C., Kulisek, N., Mundayat, R., Lawendy, N., Vranic, I., Modesto, I., Su, C., & Melmed, G. Y. (2023). Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac063

Vancouver

Winthrop KL, Vermeire S, Long MD, Panés J, Ng SC, Kulisek N, et al. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac063

BibTeX
@article{Winthrop2023,
  author = {Winthrop, Kevin L and Vermeire, Séverine and Long, Millie D and Panés, Julian and Ng, Siew C and Kulisek, Nicole and Mundayat, Rajiv and Lawendy, Nervin and Vranic, Ivana and Modesto, Irene and Su, Chinyu and Melmed, Gil Y},
  title = {Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  doi = {10.1093/ibd/izac063}
}
Kostenlos starten →